litlas
Log inCreate account

David W. Dodick

Active 1995–2025

263
Papers
36,378
Citations
105
h-index
243
i10-index

Citations

Citations per year for David W. Dodick1993: 1 citations1994: 1 citations1996: 1 citations1997: 4 citations1998: 2 citations1999: 4 citations2000: 8 citations2001: 9 citations2002: 18 citations2003: 13 citations2004: 24 citations2005: 43 citations2006: 59 citations2007: 84 citations2008: 91 citations2009: 133 citations2010: 149 citations2011: 145 citations2012: 138 citations2013: 197 citations2014: 156 citations2015: 227 citations2016: 216 citations2017: 282 citations2018: 300 citations2019: 1,262 citations2020: 1,378 citations2021: 1,450 citations2022: 1,224 citations2023: 1,074 citations2024: 1,717 citations2025: 759 citations2026: 17 citations1995: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,466 citing papers, 27.9% of this breakdownUnited Kingdom: 685 citing papers, 7.8% of this breakdownItaly: 579 citing papers, 6.6% of this breakdownGermany: 532 citing papers, 6% of this breakdownChina: 461 citing papers, 5.2% of this breakdownDenmark: 398 citing papers, 4.5% of this breakdownSpain: 305 citing papers, 3.4% of this breakdownNetherlands: 245 citing papers, 2.8% of this breakdownCanada: 244 citing papers, 2.8% of this breakdownFrance: 184 citing papers, 2.1% of this breakdownAustralia: 168 citing papers, 1.9% of this breakdownJapan: 159 citing papers, 1.8% of this breakdown
0%27.9%Other 27.2%

Institutions

Fields

  • Medicine88.2%
  • Neuroscience6.7%
  • Biochemistry, Genetics and Molecular Biology1.5%
  • Health Professions0.6%
  • Psychology0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.4%
  • Other2%

Topics

  • Migraine and Headache Studies21.9%
  • Trigeminal Neuralgia and Treatments5.2%
  • Neurological Complications and Syndromes4.8%
  • Traumatic Brain Injury Research4.5%
  • Sympathectomy and Hyperhidrosis Treatments2.5%
  • Pain Mechanisms and Treatments2.5%
  • Other58.6%

Coauthors

All papers

Open in search
  1. Migraine

    Authors: Michel D. Ferrari, Peter J. Goadsby, Rami Burstein, Tobias Kurth, Cenk Ayata, Andrew Charles, Messoud Ashina, Arn M. J. M. van den Maagdenberg, David W. Dodick - Nature Reviews Disease Primers 2022 cited by 522

  2. Fremanezumab for the Preventive Treatment of Chronic Migraine

    Authors: Stephen D. Silberstein, David W. Dodick, Marcelo E. Bigal, Paul Yeung, Peter J. Goadsby, Tricia Blankenbiller, Melissa Grozinski‐Wolff, Ronghua Yang, Yuju Ma, Ernesto Aycardi - New England Journal of Medicine 2017 cited by 803

  3. Migraine

    Authors: David W. Dodick - The Lancet 2018 cited by 559

  4. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

    Authors: David W. Dodick, Messoud Ashina, Jan Lewis Brandes, David Kudrow, Michel Lantéri‐Minet, V. В. Osipova, Kerry Palmer, Hernàn Picard, Daniel D. Mikol, Robert Lenz - Cephalalgia 2018 cited by 590

  5. Evaluation of Galcanezumab for the Prevention of Episodic Migraine

    Authors: Virginia L. Stauffer, David W. Dodick, Qi Zhang, Jeffrey N. Carter, Jessica Ailani, Robert R. Conley - JAMA Neurology 2018 cited by 566

  6. Ubrogepant for the Treatment of Migraine

    Authors: David W. Dodick, Richard B. Lipton, Jessica Ailani, Kaifeng Lu, Michelle Finnegan, Joel M. Trugman, Armin Szegedi - New England Journal of Medicine 2019 cited by 347

  7. National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome

    Authors: Douglas I. Katz, Charles Bernick, David W. Dodick, Jesse Mez, Megan Mariani, Charles H. Adler, Michael L. Alosco, Laura J. Balcer, Sarah J. Banks, William Barr, David L. Brody, Robert C. Cantu, Kristen Dams-O’Connor, Yonas E. Geda, Barry D. Jordan, Thomas W. McAllister, Elaine R. Peskind, Ronald Petersen, Jennifer V. Wethe, Ross Zafonte, Éimear M. Foley, Debra Babcock, Walter J. Koroshetz, Yorghos Tripodis, Ann C. McKee, Martha E. Shenton, Jeffrey L. Cummings, Eric M. Reiman, Robert A. Stern - Neurology 2021 cited by 326

  8. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine

    Authors: David W. Dodick, Stephen D. Silberstein, Marcelo E. Bigal, Paul Yeung, Peter J. Goadsby, Tricia Blankenbiller, Melissa Grozinski‐Wolff, Ronghua Yang, Yuju Ma, Ernesto Aycardi - JAMA 2018 cited by 573

  9. Global synergistic actions to improve brain health for human development

    Authors: Mayowa Owolabi, Matilde Leonardi, Claudio L. Bassetti, Joke Jaarsma, Tadeusz Hawrot, Akintomiwa Makanjuola, Rajinder K. Dhamija, Wuwei Feng, Volker Straub, Jennifer Camaradou, David W. Dodick, Rosita Sunna, Bindu Menon, Claire Wright, Chris Lynch, Antonella Santuccione Chadha, Maria Teresa Ferretti, Anna Dé, Coriene E. Catsman‐Berrevoets, Muthoni Gichu, Cristina Tassorelli, David Oliver, Walter Paulus, Ramla K. Mohammed, Augustina Charway‐Felli, Kevin Rostásy, Valery L. Feigin, Audrey Craven, Elizabeth Cunningham, Orla Galvin, Alexandra Heumber Perry, Ericka L. Fink, Peer Baneke, Anne Helme, Joanna Laurson-Doube, Marco T. Medina, Juan David Roa, Birgit Högl, Allan O’Bryan, Claudia Trenkwalder, Jo M. Wilmshurst, Rufus Akinyemi, Joseph Yaria, David C. Good, Volker Hoemberg, Paul Boon, Samuel Wiebe, J. Helen Cross, Magali Haas, Inez Jabalpurwala, Marijeta Mojasevic, Mónica Di Luca, Paola Barbarino, Stéphanie Clarke, Sameer M. Zuberi, Paul Olowoyo, Ayomide Owolabi, Nelson M. Oyesiku, Pia C. Sundgren, Bo Norrving, Surjo R. Soekadar, Pieter A. van Doorn, Richard Lewis, Tom Solomon, Franco Servadei - Nature Reviews Neurology 2023 cited by 113

  10. A Phase‐by‐Phase Review of Migraine Pathophysiology

    Authors: David W. Dodick - Headache The Journal of Head and Face Pain 2018 cited by 497

  11. Migraine: integrated approaches to clinical management and emerging treatments

    Authors: Messoud Ashina, Dawn C. Buse, Håkan Ashina, Patricia Pozo‐Rosich, Mário Fernando Prieto Peres, Mi Ji Lee, Gisela M. Terwindt, Rashmi B. Halker Singh, Cristina Tassorelli, Thien Phu, Dimos D. Mitsikostas, David W. Dodick - The Lancet 2021 cited by 296

  12. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial

    Authors: Peter J. Goadsby, David W. Dodick, Jessica Ailani, Joel M. Trugman, Michelle Finnegan, Kaifeng Lu, Armin Szegedi - The Lancet Neurology 2020 cited by 230

  13. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine

    Authors: Richard B. Lipton, David W. Dodick, Jessica Ailani, Kaifeng Lu, Michelle Finnegan, Armin Szegedi, Joel M. Trugman - JAMA 2019 cited by 276

  14. Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study

    Authors: Dawn C. Buse, Michael L. Reed, Kristina M. Fanning, Ryan Bostic, David W. Dodick, Todd J. Schwedt, Sagar Munjal, Preeti Singh, Richard B. Lipton - The Journal of Headache and Pain 2020 cited by 307

  15. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA

    Authors: David W. Dodick, Peter J. Goadsby, Todd J. Schwedt, Richard B. Lipton, Chengcheng Liu, Kaifeng Lu, Sung Yun Yu, Lawrence Severt, Michelle Finnegan, Joel M. Trugman - The Lancet 2023 cited by 85

  16. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults

    Authors: Cristina Tassorelli, Hans‐Christoph Diener, David W. Dodick, Stephen D. Silberstein, Richard B. Lipton, Messoud Ashina, Werner J. Becker, Michel D. Ferrari, Peter J. Goadsby, Patricia Pozo‐Rosich, Shuu‐Jiun Wang - Cephalalgia 2018 cited by 385

  17. OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program

    Authors: David W. Dodick, Catherine C. Turkel, Ronald E. DeGryse, Sheena K. Aurora, Stephen D. Silberstein, Richard B. Lipton, Hans‐Christoph Diener, Mitchell F. Brin - Headache The Journal of Head and Face Pain 2010 cited by 986

  18. Adherence to oral migraine-preventive medications among patients with chronic migraine

    Authors: Zsolt Hepp, David W. Dodick, Sepideh F. Varon, Patrick Gillard, Ryan N. Hansen, Emily Beth Devine - Cephalalgia 2014 cited by 434

  19. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults

    Authors: Stephen D. Silberstein, Starr Holland, F. G. Freitag, David W. Dodick, Charles E. Argoff, Eric Ashman - Neurology 2012 cited by 889

  20. Migraine and risk of stroke

    Authors: Lise Rystad Øie, Tobias Kurth, Sasha Gulati, David W. Dodick - Journal of Neurology Neurosurgery & Psychiatry 2020 cited by 219

  21. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis

    Authors: Zsolt Hepp, David W. Dodick, Sepideh F. Varon, Jenny Chia, Nitya Matthew, Patrick Gillard, Ryan N. Hansen, Emily Beth Devine - Cephalalgia 2016 cited by 361

  22. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults

    Authors: Hans‐Christoph Diener, Cristina Tassorelli, David W. Dodick, Stephen D. Silberstein, Richard B. Lipton, Messoud Ashina, Werner J. Becker, Michel D. Ferrari, Peter J. Goadsby, Patricia Pozo‐Rosich, Shuu‐Jiun Wang, Timothy T. Houle, Thomas C. van den Hoek, Daniele Martinelli, Gisela M. Terwindt - Cephalalgia 2020 cited by 216

  23. Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences

    Authors: Richard B. Lipton, Sagar Munjal, Aftab Alam, Dawn C. Buse, Kristina M. Fanning, Michael L. Reed, Todd J. Schwedt, David W. Dodick - Headache The Journal of Head and Face Pain 2018 cited by 188

  24. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace

    Authors: Toshihiko Shimizu, Fumihiko Sakai, Hitoshi MIYAKE, Tomofumi Sone, Mitsuhiro Sato, Satoshi Tanabe, Yasuhiro Azuma, David W. Dodick - The Journal of Headache and Pain 2021 cited by 207